What is the added value of digital image analysis of HER 2 immunohistochemistry in breast cancer in clinical practice? A study with multiple platforms-Reference-Cited by-同舟云学术

What is the added value of digital image analysis of HER 2 immunohistochemistry in breast cancer in clinical practice? A study with multiple platforms

Published:2019-04 Issue:6 Volume:74 Page:917-924
ISSN:0309-0167
Container-title:Histopathology
language:en
Short-container-title:Histopathology

Author:

Koopman Timco¹^ORCID,Buikema Henk J¹,Hollema Harry¹,Bock Geertruida H²,Vegt Bert¹^ORCID

Affiliation:

1. Department of Pathology University of Groningen University Medical Center GroningenGroningen the Netherlands

2. Department of Epidemiology University of Groningen University Medical Center Groningen Groningen the Netherlands

Publisher

Wiley

Subject

General Medicine,Histology,Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/his.13812

Reference25 articles.

1. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

2. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

3. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

4. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

5. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding the spectrum of HER2 status in breast cancer: From HER2-positive to ultra-low HER2;Pathology - Research and Practice;2024-10

2. The Performance and Clinical Applicability of HER2 Digital Image Analysis in Breast Cancer: A Systematic Review;Cancers;2024-08-03

3. Best practices for achieving consensus in HER2‐low expression in breast cancer: current perspectives from practising pathologists;Histopathology;2024-07-08

4. Consensus Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2)-Low Testing in Breast Cancer in Malaysia;Cancers;2024-06-25

5. Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges;Histopathology;2024-06-06